The emerging role of the gut in chronic heart failure

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 5, 2008, Pages 632-639

  Sandek, Anja ^a   Rauchhaus, Mathias ^a   Anker, Stefan D ^a   Von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gut; Heart failure; Immune activation; Intestinal permeability; Lipopolysaccharide

Indexed keywords

BISOPROLOL; CARRIER PROTEIN; CARVEDILOL; CYTOKINE; ENALAPRIL; ENDOTOXIN; METOPROLOL;

FOOD INTAKE; GASTROINTESTINAL ABSORPTION; HEART FAILURE; HEART FUNCTION; HUMAN; INFLAMMATION; INTESTINE BLOOD FLOW; INTESTINE FLORA; INTESTINE ISCHEMIA; INTESTINE MUCOSA; INTESTINE PERFUSION; LARGE INTESTINE; MALNUTRITION; MICROCIRCULATION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SMALL INTESTINE; STOMACH ABSORPTION; CHRONIC DISEASE; DIET RESTRICTION; EATING; GASTROINTESTINAL DISEASE; INTESTINE; ISCHEMIA; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SPLANCHNIC BLOOD FLOW; VASCULARIZATION;

BACTERIA (MICROORGANISMS);

CHRONIC DISEASE; EATING; FASTING; GASTROINTESTINAL DISEASES; HEART FAILURE; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; INTESTINES; ISCHEMIA; SPLANCHNIC CIRCULATION;

EID: 58149106232     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32830a4c6e     Document Type: Review

References (91)

1. Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3:315-322.
2. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22:1527-1560.
3. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90:464-470.
4. von Haehling S, Genth-Zotz S, Anker SD, et al. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol 2002; 85:173-183.
5. Von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007; 73:298-309.
6. Jankowska EA, Ponikowski P, Piepoli MF, et al. Autonomic imbalance and immune activation in chronic heart failure- pathophysiological links. Cardiovasc Res 2006; 70:434-445.
7. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006; 27:1440-1446.
8. Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25:1021-1028.
9. Szachniewicz J, Petruk-KowalczykJ, MajdaJ, et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 2003; 90:303-308.
10. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005; 46:1019-1026.
11. Doehner W, Rauchhaus M, Godsland IF, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. Int J Cardiol 2002; 83:73-81.
12. Springer J, Filippatos G, Akashi YJ, et al. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 2006; 21:229-233.
13. SandekA, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50:1561-1569.
14. Arutyunov GP, Kostyukevich OI, Serov RA, et al. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol 2008; 125:240-245.
15. Anker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-1430.
16. von Haehling S, Anker SD. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 2005; 14:163-176.
17. Genth-ZotzS,von Haehling S, Bolger AP, et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 2002; 90:1226-1230.
18. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart- pathophysiology and therapeutic implications. Basic Res Cardiol 2004; 99:18-28.
19. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999; 27:1309-1318.
20. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock. Crit Care Clin 2000; 16:251-287.
21. Müller-Werdan U, Engelmann H, Werdan K. Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw 1998; 9:689-691.
22. Parker MM. Pathophysiology of cardiovascular dysfunction in septic shock. New Horiz 1998; 6:130-138.
23. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479-1486.
24. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-3067.
25. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103:2055-2059.
26. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20:683-693.
27. Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30:997-1001.
28. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/ anabolic imbalance in chronic heart failure: the importance for cardiac cachexia. Circulation 1997; 96:526-534.
29. Anker SD, Ponokowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050-1053.
30. Strassburg S, Anker SD. Metabolic and immunologic derangements in cardiac cachexia: where to from here? Heart Fail Rev 2006; 11:57-64.
31. Rauchhaus M, Müller-Werdan U. Cytokines in heart diseases. Internist 2001; 42:75-84.
32. SandekA, Utchill S, Rauchhaus M. The endotoxin-lipoprotein hypothesis- an update. Arch Med Sci 2007; 3:81-90.
33. Charalambous BM, Stephens RC, Feavers IM, et al. Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 2007; 28:15-23.
34. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274:R577-R595.
35. Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95:1247-1252.
36. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor α- induced apoptosis in cardiac myocytes: involvement of the sphingolipid signalling cascade in cardiac cell death. J Clin Invest 1996; 98:2854-2865.
37. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999; 33:959-965.
38. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 1999; 33:415-424.
39. Aubert A, Goodall G, Dantzer R. Compared effects of cold ambient temperature and cytokines on macronutrient intake in rats. Physiol Behav 1995; 57:869-873.
40. Doig CJ, Sutherland LR, Sandham JD, et al. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. Am J Respir Crit Care Med 1998; 158:444-451.
41. Deitch EA. Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings? Surgery 2002; 131:241-244.
42. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34:32-37.
43. Riddington DW, Venkatesh B, Boivin CM, et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996; 275:1007-1012.
44. Peschel T, Schonauer M, Thiele H, et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2003; 5:609-614.
45. Parks DA, Jacobson ED. Physiology of splanchnic circulation. Arch Intern Med 1985; 145:1278-1281.
46. Ralevic V. Splanchnic circulatory physiology. Hepato-gastroenterology 1999; 46:1409-1413.
47. Takala J. Determinants of splanchnic blood flow. BrJ Anaesth 1996; 77:50-58.
48. Ohri SK, Becket J, Brannan J, et al. Effects of cardiopulmonary bypass on gut blood flow, oxygen utilization, and intramucosal pH. Ann Thorac Surg 1994; 57:1193-1199.
49. KrackA, Richartz BM, Gastmann A, et al. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur J Heart Fail 2004; 6:403-407.
50. Fiddian-Green RG, Baker S. Predictive value of the stomach wall pH for complications after cardiac operations: comparison with other monitoring. Crit Care Med 1987; 15:153-156.
51. Uhlig T, Kuss O, Kuppe H, et al. Gastric mucosal tonometry as a monitoring method in cardiac anaesthesia. Anasthesiol Intensivmed Schmerzther 1998; 33:S99-S105.
52. Raja K, Kochhar R, Sethy PK, et al. An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. Gastrointest Endosc 2004; 60:887-893.
53. Sondheimer JM, Hamilton JR. Intestinal function in infants with severe congenital heart disease. J Pediatr 1978; 92:572-578.
54. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 2000; 102:2700-2706.
55. King D, Smith ML, Chapman TJ, et al. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing 1996; 25:144-149.
56. Reid JA, Annamalai G, Lau LL, Soong CV. Intra-mucosal acidosis as a predictor of cardiac outcome following abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004; 28:353-356.
57. Nessar G, Kucukaksu S, Zengin NI, et al. Ischemic necrosis of the right colon in a patient with a ventricular assist device system. Tech Coloproctol 2007; 11:275-277.
58. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113:1424-1433.
59. Abraham C, Cho JH. Bugging of the intestinal mucosa. N Engl J Med 2007; 357:708-710.
60. Alverdy JC, Spitz J, Hecht G, et al. Causes and consequences of bacterial adherence to mucosal epithelia during critical illness. New Horiz 1994; 2:264-272.
61. Alverdy J, ZaborinaO, Wu L. The impact of stress and nutrition on bacterialhost interactions at the intestinal epithelial surface. Curr Opin Clin Nutr Metab Care 2005; 8:205-209.
62. Conraads VM, Jorens PG, De Clerck LS, et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 2004; 6:483-491.
63. Pirlich M, Norman K, Lochs H, et al. Role of intestinal function in cachexia. Curr Opin Clin Nutr Metab Care 2006; 9:603-606.
64. Hayden UL, Carey HV. Neural control of intestinal ion transport and paracellular permeability is altered by nutritional status. Am J Physiol Regul Integr Comp Physiol 2000; 278:R1589-R1594.
65. Ogata Y, Nishi M, Nakayama H, et al. Role of bile in intestinal barrier function and its inhibitory effect on bacterial translocation in obstructive jaundice in rats. J Surg Res 2003; 115:18-23.
66. Wells CL, Jechorek RP, Erlandsen SL. Inhibitory effect of bile on bacterial invasion of enterocytes: possible mechanism for increased translocation associated with obstructive jaundice. Crit Care Med 1995; 23:301-307.
67. Jarvis RC, Green JA, Nara AR, et al. Effects of food ingestion on hemodynamics in chronic congestive heart failure. Crit Care Med 1988; 16:491-494.
68. Siemienczuk D, Greenberg B, Broudy DR. Effects of eating on cardiac performance in congestive heart failure. Chest 1986; 90:193-197.
69. Muller AF, Hawkins M, Batin P, et al. Food in chronic heart failure: improvement in central haemodynamics but deleterious effects on exercise tolerance. Eur Heart J 1992; 13:1460-1467.
70. Krack A, Sharma R, Figulla HR, et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005; 26:2368-2374.
71. Krohg-Sørensen K, Lunde OC. Perfusion of the human distal colon and rectum evaluated with endoscopic laser Doppler flowmetry. Methodologic aspects. Scand J Gastroenterol 1993; 28:104-108.
72. 2. Crit Care Med 1998; 26:1479-1481.
73. Dantzker D. The gastrointestinal tract: the canary of the body? JAMA 1993; 270:1247-1248.
74. Gutierrez G, Palizas F, DoglioG, et al. Gastric intramucosal pH as therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992; 339:195-199.
75. Solligård E, Wahba A, Skogvoll E, et al. Rectal lactate levels in endoluminal microdialysate during routine coronary surgery. Anaesthesia 2007; 62:250-258.
76. Uddin N, Patterson JH. Current guidelines for treatment of heart failure: 2006 update. Pharmacotherapy 2007; 27:12S-17S.
77. Brass CA, Crawford JM, Narciso J, Gollan JL. Hypoxic liver injury and the ameliorating effects of fructose: the 'glucose paradox' revisited. Am J Physiol 1992; 263:G293-G300.
78. CellarierG, Bonal J, BouchiatC, et al. Acute ischemic liver. Presse Med 1995; 24:1418-1420.
79. Shibayama Y. Enhanced hepatotoxicity of endotoxin by hypoxia. Pathol Res Pract 1987; 182:390-395.
80. Kadaoui KA, Corthesy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol 2007; 179:7751-7757.
81. Flierl MA, Rittirsch D, Nadeau BA, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007; 449:721-725.
82. Werner S, Werdan K, Ponicke K, et al. Impaired beta-adrenergic control of immune function in patients with chronic heart failure: reversal by beta1-blocker treatment. Basic Res Cardiol 2000; 96:290-298.
83. Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101:865-869.
84. Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31:43-48.
85. Kincaid EH, Miller PR, Meredith JW, et al. Enalaprilat improves gut perfusion in critically injured patients. Shock 1998; 9:79-83.
86. McVay MR, Boneti C, Habib CM, et al. Formula fortified with live probiotic culture reduces pulmonary and gastrointestinal bacterial colonization and translocation in a newborn animal model. J Pediatr Surg 2008; 43:25-29.
87. Gatt M, Reddy BS, MacFie J. Review article: bacterial translocation in the critically ill- evidence and methods of prevention. Aliment Pharmacol Ther 2007; 25:741-757.
88. Fox ES, Leingang KA. Inhibition of LPS-mediated activation in rat Kupffer cells by N-acetylcysteine occurs subsequent to NF-kappaB translocation and requires protein synthesis. J Leukoc Biol 1998; 63:509-514.
89. RankN, Michel C, Haertel C, et al. N-Acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med 2001; 28:3799-3807.
90. Schefold JC, von Haehling S, Corsepius M, et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 2007; 28:418-425.
91. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a nonspecific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008; 371:228-236.